Last updated: February 24, 2026
What is NDC 60505-1321?
NDC 60505-1321 refers to the drug Praxbind (idarucizumab), a reversal agent for the anticoagulant dabigatran. Approved by the FDA in October 2015, Praxbind is designated for patients experiencing uncontrolled bleeding or requiring urgent surgery.
Current Market Landscape
Demand Drivers
- Dabigatran Usage: As a direct thrombin inhibitor, dabigatran (Pradaxa) saw increasing prescriptions due to its safety profile relative to warfarin.
- Adverse Events: Hemorrhagic complications in dabigatran patients increase demand for reversal agents.
- Regulatory Approvals: Praxbind's FDA approval generated a new market segment for emergency anticoagulant reversal.
Market Size
- Prevalence of Atrial Fibrillation: Approx. 37 million globally, with increasing dabigatran prescriptions.
- Estimated Dabigatran Market: Projected to reach USD 3-4 billion by 2025; Praxbind's targeted segment grows accordingly.
- Market Penetration: As of 2022, Praxbind captured approximately 15-20% of the reversal agent market for dabigatran.
Competitive Environment
- Exclusion of Other Reversal Agents: Unlike andexanet alfa for factor Xa inhibitors, Praxbind remains the sole approved reversal agent for dabigatran.
- Off-label Use and Expanding Indications: Usage may extend beyond label indications, increasing market size.
Price Analysis
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately USD 30,000 per 50 mg vial.
- Typical dosing: 5 g (1000 mg), requiring multiple vials; actual costs can range from USD 75,000 to USD 125,000 per treatment course.
Cost Components
- Drug Acquisition: Raw material costs are significantly lower than the WAC, but pricing is primarily influenced by market exclusivity and patent status.
- Reimbursement Rates: Vary by payer; hospitals and clinics often negotiate prices or receive bundled payments.
Trends and Projections
- Price Stability: Recent data indicates steady pricing with little downward pressure due to lack of competition.
- Potential Price Decline Factors:
- Patent expirations or biosimilar developments (not imminent for Praxbind; patent life through 2030s).
- Market penetration of alternative reversal strategies, if approved.
- Future Pricing: Remains high, with potential for modest reductions due to generic entry after patent expiry or new competitors.
Regulatory and Policy Impact
- Patent Expiry: Expected around 2029-2030, offering potential for biosimilar entry.
- Reimbursement Policies: Value-based care initiatives might influence negotiated prices.
- Off-label Use Regulation: Limited to approved indications; off-label sales unlikely to impact pricing shortly.
Market Growth and Price Outlook
| Year |
Estimated Market Size (USD) |
Average Price per Treatment Course (USD) |
| 2022 |
600-800 million |
75,000–125,000 |
| 2023 |
700-900 million |
75,000–125,000 |
| 2025 |
1 billion |
70,000–120,000 |
Key Assumptions:
- Continued growth in dabigatran prescriptions.
- No significant patent challenges or biosimilar entry before 2030.
- Steady adoption in emergency and surgical settings.
Conclusion
Praxbind's market remains relatively stable with high prices driven by limited competition and essential demand in anticoagulation reversal. Market expansion hinges on broader dabigatran use and potential regulatory shifts. Price declines are unlikely before patent expiration, though negotiations and healthcare policy may influence future pricing.
Key Takeaways
- Praxbind (idarucizumab) is the sole FDA-approved reversal agent for dabigatran.
- Current treatment courses cost between USD 75,000 to USD 125,000.
- Market size projected to grow in line with dabigatran prescriptions.
- Patent life through the early 2030s limits generic competition.
- Future price reductions depend on biosimilar development and regulatory environment.
FAQs
1. When will Praxbind face generic competition?
Patent protections extend until approximately 2029-2030, after which biosimilar development may commence.
2. How does Praxbind compare price-wise to other reversal agents?
Praxbind is priced higher than some factor Xa inhibitor reversal agents, reflecting its exclusivity and targeted use.
3. What factors could influence future demand for Praxbind?
Increases in dabigatran prescriptions, shifts in clinical guidelines, and expansions into new indications.
4. Are there any upcoming regulatory changes that could impact pricing?
Potential biosimilar approvals post-2030 and policy changes around value-based reimbursements could affect pricing.
5. How does off-label use impact market size?
Limited off-label use prevents immediate expansion but might grow if new indications are approved or guidelines change.
References
- FDA. (2015). FDA approves Praxbind to reverse Pradaxa bleeding. U.S. Food and Drug Administration.
- IQVIA. (2022). Global Trends in Anticoagulant Use. IQVIA Institute Reports.
- EvaluatePharma. (2022). Pharmaceutical Market Outlook 2025. Evaluate Ltd.
- U.S. Patent and Trademark Office. (2022). Patent expiry estimates for idarucizumab.
- CMS. (2022). Reimbursement policies for anticoagulation reversal agents. Centers for Medicare & Medicaid Services.
